Literature DB >> 10720645

Antiangiogenic effects of S-nitrosocaptopril crystals as a nitric oxide donor.

L Jia1, C C Wu, W Guo, X Young.   

Abstract

Angiogenesis is the formation of new capillaries from preexisting vessels by migration and proliferation of endothelial cells, which produce a cellular signaling messenger, nitric oxide (NO). The purpose of the present study was to examine the effects of exogenous NO donors on angiogenesis by using a novel crystalline NO donor, S-nitrosocaptopril. The characteristic X-ray diffraction pattern of S-nitrosocaptopril was demonstrated for the first time. On primary capillary endothelial cells pretreated with vascular endothelium growth factor (VEGF), S-nitrosocaptopril (1-500 microM), but not captopril, produced a dose-dependent inhibition of endothelial proliferation. On chick embryos of entire living eggs, gelatin sponges adsorbed with VEGF were implanted on the embryo chorioallantoic membrane to promote vascular growth activity within the sponges. Addition of S-nitrosocaptopril crystals (0.1 mg) to the gelatin sponges markedly reduced vascular density around the sponges, whereas captopril did not inhibit neovascularization. The vascular hemoglobin content surrounding each of the gelatin sponges was determined as a confirmatory test. S-nitrosocaptopril, but not captopril, significantly decreased the hemoglobin content of the embryo tissues immediately surrounding the gelatin sponges. In conclusion, S-nitrosocaptopril exerts an inhibitory effect on angiogenesis. This newly discovered function of S-nitrosocaptopril appears to be governed by distinct structural NO moiety.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720645     DOI: 10.1016/s0014-2999(99)00794-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.

Authors:  Tanyel Kiziltepe; Kenneth C Anderson; Jeffery L Kutok; Lee Jia; Kenneth M Boucher; Joseph E Saavedra; Larry K Keefer; Paul J Shami
Journal:  J Pharm Pharmacol       Date:  2010-01       Impact factor: 3.765

Review 2.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

3.  In vitro and in vivo assessment of cellular permeability and pharmacodynamics of S-nitrosylated captopril, a nitric oxide donor.

Authors:  L Jia; H Wong
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

4.  Quantitative determination of tumor cell intravasation in a real-time polymerase chain reaction-based assay.

Authors:  Emilia Mira; Rosa Ana Lacalle; Concepción Gómez-Moutón; Esther Leonardo; Santos Mañes
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

5.  Nitric oxide inhibits hetero-adhesion of cancer cells to endothelial cells: restraining circulating tumor cells from initiating metastatic cascade.

Authors:  Yusheng Lu; Ting Yu; Haiyan Liang; Jichuang Wang; Jingjing Xie; Jingwei Shao; Yu Gao; Suhong Yu; Shuming Chen; Lie Wang; Lee Jia
Journal:  Sci Rep       Date:  2014-03-11       Impact factor: 4.379

Review 6.  The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis.

Authors:  Domenico Ribatti
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.